Neumora Therapeutics, Inc. Common Stock (NMRA) financial statements and ratios from SEC XBRL: revenue $8.34M (TTM), net margin -2839.5%, revenue growth -58.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $8.34M |
| Net Margin | -2839.5% |
| Revenue Growth (YoY) | -58.1% |
| EPS Growth (YoY) | -5.2% |
| Price / Book | 6.84 |
| Price / Sales | 59.90 |
| FCF Yield | -52.1% |
| Altman Z-Score | -9.78 (distress) |
| Sector P/E (Healthcare) | 21.7 |
NMRA overview · NMRA earnings · NMRA KPIs · NMRA investor relations · NMRA ownership · NMRA peers · NMRA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.